Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Role of the NaV1.7 R1150W amino acid change in susceptibility to symptomatic knee osteoarthritis and multiple regional pain

Tools
- Tools
+ Tools

Valdes, Ana M., Arden, N., Vaughn, Frances L., Doherty, Sally A., Leaverton, Paul E., Zhang, Weiya, Muir, Kenneth, Rampersaud, Evadnie, Dennison, Elaine M., Edwards, Mark H., Jameson, Karen A., Javaid, M. Kassim, Spector, T. D., Cooper, Cyrus, Maciewicz, Rose A. and Doherty, Michael (2011) Role of the NaV1.7 R1150W amino acid change in susceptibility to symptomatic knee osteoarthritis and multiple regional pain. Arthritis Care & Research, Vol.63 (No.3). pp. 440-444. doi:10.1002/acr.20375

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1002/acr.20375

Request Changes to record.

Abstract

Objective. To assess the genetic association of pain in patients with knee osteoarthritis (OA) and those with multiple regional pain with the R1150W variant in the alpha-subunit of the voltage-gated sodium channel Na(V)1.7.

Methods. Knee OA patients from 2 UK cohorts (1,411 from the Genetics of Osteoarthritis and Lifestyle study and 267 from the Hertfordshire Cohort Study; 74% with symptomatic OA) with Western Ontario and McMaster Universities OA Index (WOMAC) pain scores were genotyped for rs6746030 (encoding the R1150W change). One hundred seventy-six knee OA patients (53% symptomatic) from the Clearwater Osteoarthritis Study were also tested. A total of 4,295 samples (both affected and unaffected OA) from all 3 studies with data on multiple regional pain were tested. Fixed-effects meta-analyses were carried out with the WOMAC, symptomatic OA (adjusting for radiographic severity), and multiple regional pain as outcomes.

Results. No association with the WOMAC was seen in the UK cohorts. Overall, the meta-analysis of WOMAC yielded a summary statistic of beta = 0.47 (95% confidence interval [95% CI] 0.04, 0.89; P = 0.030) for the variant allele. The meta-analysis of symptomatic versus asymptomatic OA did not demonstrate an association with rs6746030 (odds ratio [OR] 0.90 [95% CI 0.71, 1.15], P = 0.38). The meta-analysis of multiple regional pain resulted in a significant OR of 1.40 (95% CI 1.08, 1.80; P = 0.0085). No interstudy heterogeneity was seen for any of the analyses.

Conclusion. We find evidence that the R1150W amino acid change in the Na(V)1.7 alpha-chain is associated with multiple regional pain. This variant is confirmed to be involved in genetic susceptibility to pain, but it does not appear to have a major role in OA-specific pain.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Osteoarthritis -- Pathogenesis, Knee -- Diseases, Cohort analysis -- Great Britain, Amino acids -- Physiological effect
Journal or Publication Title: Arthritis Care & Research
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 2151-464X
Official Date: March 2011
Dates:
DateEvent
March 2011Published
Volume: Vol.63
Number: No.3
Page Range: pp. 440-444
DOI: 10.1002/acr.20375
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Seventh Framework Programme (European Commission) (FP7), AstraZeneca (Firm), Arthritis Research UK , Medical Research Council (Great Britain) (MRC), National Institute for Health Research (Great Britain) (NIHR)
Grant number: 200800 (FP7), 14581 (ARUK)

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us